Covid 19 Research using Clinical Trials (Home Page)
Report for D006331: Heart Diseases NIH
(Synonyms: Heart Di, Heart Dis, Heart Dise, Heart Diseas, Heart Disease, Heart Diseases)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Impact of Covid-19 in Congenital Heart Disease - COVID-CHD
The ongoing Coronavirus (Covid-19) pandemic has recently generated the first epidemiological data on populations at risk. Currently, the risk factors, recognized for severe forms of Covid-19 infection, are elderly patients (> 70 years), obese patients, patients with chronic renal or respiratory diseases, cardiovascular history (stroke or coronary artery disease), high blood pressure, diabetes, and cancer. The population of congenital heart disease (CHD) might also be at risk, however, no data is available in this group of patients. CHD is the leading cause of birth defects, and as a result of recent medical advances, currently the number of adults with CHD exceeds the number of children, with an increasing prevalence of complex CHD. Approximately 200,000 children and 250,000 adults are living with a CHD in France today. The French Society of Cardiology, coordinator of this study, issued recommendations on March 14, 2020 for the French CHD population on the basis of expert opinions based essentially on the data published in the general population. Nevertheless, there is a need to provide scientific data on the impact of Covid-19 in the pediatric and adult CHD population. This study aims to assess the morbidity, the mortality and the risk factors associated with Covid-19 in patients with CHD in France
NCT04336384 Congenital Heart Disease Covid-19 MeSH:Heart Diseases Heart Defects, Congenital
HPO:Abnormal heart morphology
Primary Outcomes
Description: Prevalence of Covid-19 infection in the overall CHD population
Measure: Prevalence of Covid-19 infection in the overall CHD population Time: through study completion, an average of 2 weeks
Secondary Outcomes
Description: Prevalence of Covid-19 infection per CHD sub-group
Measure: Prevalence of Covid-19 infection per CHD sub-group Time: through study completion, an average of 2 weeks
Description: Cardiovascular complications
Measure: Cardiovascular complications Time: through study completion, an average of 2 weeks
Description: Other complications
Measure: Other complications Time: through study completion, an average of 2 weeks
Description: Number of deaths
Measure: Number of deaths Time: through study completion, an average of 2 weeks
HPO Nodes
Primary Outcomes
Description: Prevalence of Covid-19 infection in the overall CHD population
Measure: Prevalence of Covid-19 infection in the overall CHD population Time: through study completion, an average of 2 weeksSecondary Outcomes
Description: Prevalence of Covid-19 infection per CHD sub-group
Measure: Prevalence of Covid-19 infection per CHD sub-group Time: through study completion, an average of 2 weeksDescription: Cardiovascular complications
Measure: Cardiovascular complications Time: through study completion, an average of 2 weeksDescription: Other complications
Measure: Other complications Time: through study completion, an average of 2 weeksDescription: Number of deaths
Measure: Number of deaths Time: through study completion, an average of 2 weeks